JD Vance Predicts: Wall Street vs. Trump & Your Money

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Henry A. Fernandez net worth and biography

Henry Fernandez Biography and Net Worth

Director of Royalty Pharma

Henry A. Fernandez has served as Director and Chairman of MSCI Inc. since 2007 and as Chief Executive Officer since 1998. Before leading MSCI’s transition to becoming a fully independent, public company in 2007, he was a Managing Director at Morgan Stanley from 1983 to 1991 and from 1994 to 2007, where he worked in emerging markets product strategy, equity derivative sales and trading, mergers and acquisitions, worldwide corporate finance and mortgage finance for U.S. financial institutions. Mr. Fernandez serves on the Board of Trustees for Stanford University as well as Memorial Sloan Kettering Cancer Center. Mr. Fernandez holds a Bachelor of Arts in economics from Georgetown University, an MBA from the Stanford University Graduate School of Business and pursued doctoral studies in economics at Princeton University.

What is Henry A. Fernandez's net worth?: The estimated net worth of Henry A. Fernandez is at least $8.59 million as of April 25th, 2024. Mr. Fernandez owns 327,479 shares of Royalty Pharma stock worth more than $8,586,499 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Fernandez may own. Learn More about Henry A. Fernandez's net worth.
How do I contact Henry A. Fernandez?: The corporate mailing address for Mr. Fernandez and other Royalty Pharma executives is 110 E 59th Street, New York NY, 10022. Royalty Pharma can also be reached via phone at 212-883-0200 and via email at [email protected]. Learn More on Henry A. Fernandez's contact information.
Has Henry A. Fernandez been buying or selling shares of Royalty Pharma?: Henry A. Fernandez has not been actively trading shares of Royalty Pharma in the last ninety days. Most recently, on Thursday, February 24th, Henry A. Fernandez bought 32,500 shares of Royalty Pharma stock. The stock was acquired at an average cost of $37.49 per share, with a total value of $1,218,425.00. Learn More on Henry A. Fernandez's trading history.
Who are Royalty Pharma's active insiders?: Royalty Pharma's insider roster includes Terrance Coyne (CFO), Henry Fernandez (Director), William Ford (Director), Mario Giuliani (Director), Pablo Legorreta (CEO), George Lloyd (EVP), James Reddoch (EVP), Rory Riggs (Director), Sanjay Singh (CRO), and Marshall Urist (EVP). Learn More on Royalty Pharma's active insiders.
Are insiders buying or selling shares of Royalty Pharma?: In the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 312,631 shares worth more than $8,860,323.39. The most recent insider tranaction occured on January, 4th when Director Rory B Riggs sold 35,702 shares worth more than $983,590.10. Insiders at Royalty Pharma own 18.9% of the company. Learn More about insider trades at Royalty Pharma.
Information on this page was last updated on 1/4/2024.

Henry A. Fernandez Insider Trading History at Royalty Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/24/2022	Buy	32,500	$37.49	$1,218,425.00
2/25/2021	Buy	25,700	$46.83	$1,203,531.00	8,713

Henry A. Fernandez Buying and Selling Activity at Royalty Pharma

Royalty Pharma Company Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Today's Range

Now: $26.22

$25.80

$26.29

50 Day Range

MA: $27.35

$25.58

$28.38

2 Week Range

Now: $26.22

$25.10

$31.66

Volume

2,003,795 shs

Average Volume

2,933,160 shs

Market Capitalization

$15.45 billion

P/E Ratio

13.59

Dividend Yield

3.23%

Beta

0.47